



STATISTICAL ANALYSIS PLAN

Red Blood Cell Transfusion Paper

Version 6

December 21th, 2023

Principal investigators:

Prof. Dr. E. Lopriore

Prof. Dr. J.G. van der Bom

Prof. Dr. C.J. Fijnvandraat

Dr. S.F. Fustolo-Gunnink

Prof. Dr. Christof Dame

Dr. Charles Roehr

Dr. Emöke Deschmann

Prof. Dr. Simon Stanworth

Dr. Helen New

Biostatistician:

Prof. dr. Le Cessie

Data-manager:

Dr. Camila Caram Deelder

Coordinating investigator:

N.A.M. Houben, PhD student

ISRCTN registry:

Registration number ISRCTN17267090

TABLE OF CONTENTS

1. STUDY SUMMARY	3
2. STUDY OUTCOME MEASURES	4
2.1 Study outcome measures describing RBC transfusion use	4
2.2 Other study outcome measures	4
3. DATA CLEANING	5
3.1 Data cleaning during study follow-up	5
3.2 Data cleaning after completion study follow-up	5
4. DATA ANALYSES	6
4.1 General remarks.....	6
4.2 Missing data.....	6
4.3 Data transformations.....	7
4.4 Patient and center characteristics	8
5. ANALYSIS OF STUDY OUTCOME MEASURES DESCRIBING RBC USE	9
5.1 RBC transfusion day prevalence rates.....	9
5.2 Case-mix adjusted RBC transfusion day prevalence rates.....	10
5.3 Cumulative incidence of receiving at least one RBC transfusion	11
6. ANALYSIS FOR OTHER STUDY OUTCOME MEASURES	12
6.1 Primary indications for RBC transfusion.....	12
6.2 Transfusion volume, duration and infusion rate	12
6.3 Haemoglobin values prior to transfusion	12
6.4 RBC transfusion Haemoglobin increment.....	14
6.5 Transfusion related adverse effects after RBC transfusion.....	14
7. GENERAL REMARKS.....	15
8. STATEMENT	16
9. REFERENCES.....	17


1. STUDY SUMMARY

Study rationale: Premature infants are a highly transfused group, though robust evidence supporting neonatal transfusion practice is scarce. Two randomized trials (the ETTNO and TOP trial) were recently published, indicating no benefit in long-term outcomes when using liberal (high) thresholds for red blood cell (RBC) transfusions. (1, 2) There are no neonatal transfusion guidelines that have been implemented by Europe as a whole, resulting in significant variation in transfusion practice within Europe. Detailed contemporary data on neonatal transfusion practices in Europe, including the use of red blood cells (RBC), platelets and plasma transfusion, are lacking.

Study population: preterm infants born below 32 weeks gestation admitted to a tertiary level Neonatal Intensive Care Unit (NICU)

Study design: prospective, international, multicenter, observational study

Study data collection: data collection took place from September 2022 to August 2023. All participating centers collected data during a fixed six-week study period. Local sites documented transfusion use in all infants in their NICU during these weeks, including infants already admitted at the start of the study period or newly admitted during the study period. Consequently, not all infants were followed from birth, and the duration of study follow-up varied, with a maximum follow-up of 42 days per included patient.



Infographic was made using images of Juicy_Fish from FlatIcon.

2. STUDY OUTCOME MEASURES

We aim to publish separate papers describing neonatal RBC, platelet and plasma transfusions. Therefore, this SAP only focuses on the use of RBCs.

2.1 Study outcome measures describing RBC transfusion use

1. RBC transfusion day prevalence rates during first 28 postnatal days of life
2. RBC transfusion day prevalence rates after first 28 postnatal days of life
3. Case-mix adjusted RBC transfusion day prevalence rates during first 28 days
4. Case-mix adjusted RBC transfusion day prevalence rates after first 28 days
5. Cumulative incidence of receiving at least one RBC transfusion during first 28 days of life

2.2 Other study outcome measures

6. Primary indications for RBC transfusion
7. Volume, duration and infusion rate of RBC transfusion
8. Hemoglobin (Hb) levels prior to RBC transfusion
9. Transfusion Hb increment, stratified for transfusion volume
10. Transfusion related adverse effects

3. DATA CLEANING

3.1 Data cleaning during study follow-up

The site specific patient data was checked and cleaned after the completion of the study period in that participating center. This data quality check was used to detect outliers and impossible combinations of data entry (e.g. non-chronological dates, transfusions after end of study follow-up , etc.). Additionally, we checked for missing data in the baseline characteristics and outcome data. In case of missing data or ambiguities, the local investigator was contacted and incorrect values were directly corrected in the data management system Castor.

3.2 Data cleaning after completion study follow-up

A final data quality check will be performed once all the centers completed the study period using the same data quality check code. Possible ambiguities that were overlooked during the center specific check will be corrected, where any modifications made will be recorded in the data cleaning code.

4. DATA ANALYSES

4.1 General remarks

All statistical analyses will be performed using R statistical software (Version 4.1.17, R Core Team, 2021) or STATA statistical Software (Version 16.1, Texas, USA). Continuous data will be presented as mean (standard deviation (SD)) or as median (interquartile range (IQR)), where appropriate.

4.2 Missing data

Missing values were limited in the eCRF since the majority of the collected variables were marked as mandatory to fill in. Therefore, we expect very few missing values in the dataset.

We decided in advance how to handle missing data for the following variables:

Variables	Commentary
Hb level prior to transfusion	Only recorded if Hb was available in the 24 hours before transfusion. If left blank, the value is recorded as 'not available'.
Hb level after transfusion	Only recorded if a Hb was available in the 24 hours after transfusion. If left blank, the value is recorded as 'not available'.
Number of blood tests per postnatal day	It was possible to leave the number of blood tests per test open in the tables. If left blank, the value is recorded as '0' under the assumption that centers most likely left them open to save time when a test has not been taken.
Congenital anomalies	If not recorded, we assume that congenital anomalies were unlikely and the value is recorded as '0'.
Bleeding disorders	If not recorded, we assume bleeding disorders were not present and the value is recorded as '0'.
Major bleeding	If not recorded we assume no major bleeding occurred and the value is recorded as '0'.
NEC	If not recorded, we assume no NEC occurred and the value is recorded as '0'.
Sepsis	If recorded as unknown, we assume no sepsis occurred and the value is recorded as '0'.
Mechanical ventilation	If recorded as unknown, we assume no mechanical ventilation occurred and the value is recorded as '0'.
Surgical procedures	If recorded as unknown, we assume no surgical procedures occurred and the value is recorded as '0'.

For all other variables, the total number of missing values will be reported, with the number of infants who had one or more missing values for the variable.

4.3 Data transformations

For the clinical events, investigators only collected the start date of clinical events (except mechanical ventilation) so no information is available on the duration of the event or the time to clinical remission. Therefore, we made assumptions about the duration of clinical events, which allows us to use these variables for the case-mix adjusted prevalence rates.

The variables for clinical events were defined as followed:

Clinical events	Definitions
Major bleeding	<p>The duration of a major bleeding episode is defined as 7 days from the day of detection of the major bleeding. For each individual admission day, one of the values will be assigned:</p> <ul style="list-style-type: none"> – 0: No major bleeding – 1: Current bleeding episode – 2: Status post bleeding
NEC	<p>The duration of a NEC episode is defined as 7 days from the day of the first symptoms. For each individual admission day, one of the values will be assigned:</p> <ul style="list-style-type: none"> – 0: No NEC – 1: Current NEC episode – 2: Status post NEC
Sepsis	<p>The duration of a sepsis episode is defined as 7 days from the day of the positive blood culture. For each individual admission day, one of the values will be assigned:</p> <ul style="list-style-type: none"> – 0: No sepsis – 1: Current sepsis episode – 2: Status post sepsis
Mechanical ventilation	<p>The duration of a mechanical ventilation episode is defined as the period from the postnatal day of start mechanical ventilation until the postnatal day of stop mechanical ventilation. For each individual admission day, one of the values will be assigned:</p> <ul style="list-style-type: none"> – 0: No mechanical ventilation – 1: Current mechanical ventilation episode – 2: Status post mechanical ventilation
Surgical procedures	<p>The duration of a surgical procedure episode is defined as 7 days from the day of the surgical procedure. For each individual admission day, one of the values will be assigned:</p> <ul style="list-style-type: none"> – 0: No surgical procedure – 1: Current surgy episode – 2: Status post surgery

For these assigned values, it is not possible for infants to go back to a status with a lower value, example given from “1” to “0”.

Example. Patient A was followed in the study from postnatal day 1 (equal to day of birth) to postnatal day 28, during which the patient developed a culture proven sepsis episode on day 4. In the study database, the patient was represented by 28 rows each representing one admission day in study follow-up. For this sepsis episode, day 4 and the following six days until day 10 were recorded as “1”. Prior to sepsis, day 1 to 3 were recorded as “0” (no sepsis), day 11 to 28 as “2” (status post sepsis).

4.4 Patient and center characteristics

The following descriptive data on patient and center characteristics will be presented.

Patient characteristics (for total and per country)

- Number of patient included
- Total number of admission days in study follow-up
- Duration of study follow-up per patient, in days
- Postnatal age at start follow-up in the study, in days
- Sex, % female
- Gestational age at birth, in days
- Birth weight, in grams
- Multifetal pregnancy, % singleton
- Patients with congenital anomalies, %
- Patients with congenital bleeding disorders, %
- Patients with at least one major bleeding during study follow-up, %
- Patients with at least one NEC episode during study follow-up, %
- Patients with at least one sepsis episode during study follow-up, %
- Patients with at least one day of mechanical ventilation during study follow-up, %
- Patients with at least one surgical procedure during study follow-up, %

Participating centers (for total and per country)

- Number of academic centers, %
- Number of centers that perform NEC surgery, %
- Number of larger centers (caring >100 preterm infants with a GA below 32 weeks yearly on average), %
- Number of centers with RBC transfusion guideline with specific recommendations for preterm infants, %

5. ANALYSIS OF STUDY OUTCOME MEASURES DESCRIBING RBC USE

5.1 RBC transfusion day prevalence rates

The prevalence rate is the rate of events (new and recurring events) over a specified time period. The RBC transfusion day prevalence rate in a certain time period is defined as the number of RBC transfusion days per 100 NICU admission days in this period. A RBC transfusion day is defined as any day after birth on which the infant received at least one RBC transfusion.

$$\text{Prevalence rate} = \frac{\text{Number of RBC transfusions days during study period}}{\text{Number of admission days in follow up during study period}} \times 100 \text{ days}$$

The RBC transfusion prevalence rate is calculated in each center and pooled per country. We expect a large between country variability, therefore all prevalence rates are pooled using random effects Poisson models described by Stijnen et al. (2010). This model uses the exact within-study likelihood instead of the approximate normal within-study likelihood which is known to perform better with low event rates and small sample sizes. Additionally, this method does not require the use of a continuity correction in case centers have a prevalence rate of 0 RBC transfusion days. (3) Pooling is done using the function “metarate” of the R-package Meta.

Subgroup rates and overall rate will be presented with 95% confidence intervals in a forest plot. Prevalence rates will only be presented on country level.

We will present two forest plots of the RBC transfusion day prevalence rate, separately for the first 28 postnatal days of life and after the first 28 days of life. We selected this 28-day cutoff based on admission patterns, with very preterm infants being admitted to the NICU primarily due to their prematurity in the initial weeks after birth. Infants in need of neonatal intensive care after the first month of life constitute a more diverse group, often characterized by a broader range of specific comorbidities.

5.2 Case-mix adjusted RBC transfusion day prevalence rates

As variation between countries in RBC prevalence rates could be explained by differences in population characteristics and disease severity, we will calculate case-mix adjusted RBC transfusion day prevalence rates adjusted for several patient demographics and clinical variables to allow fair comparison between prevalence rates.

Case-mix adjusted RBC transfusion day prevalence rates will be calculated as followed:

1. A logistic regression model is fitted on all data, with case-mix variables and clinical variables as (possible time varying) predictors and RBC transfusion as response variable.
2. The model is used to estimate the expected RBC transfusion day prevalence rate per country
3. Observed / expected prevalence rate ratio per country are calculated
4. Rate ratio are multiplied with overall unadjusted RBC prevalence rate

5.2.1. Average expected RBC transfusion day prevalence rate per country

A logistic regression model is used to estimate the probability that a NICU admission day is a RBC transfusion day based on several covariables, for each individual admission day in study follow-up. To account for the repeated measures within an infant, the model is fitted using generalized estimation equations (GEE).

The analyses will be performed separately for the two distinct periods: the first 28 postnatal days of life and after the first 28 days of life. Probabilities are calculated individually for each patient for each NICU admission day in study follow-up and summarized per country to calculate the average predicted RBC transfusion day prevalence rate.

Average expected RBC transfusion day prevalence rate per country =

$$\frac{\text{Sum of predicted probability per admission day over admission days over infants per country}}{\text{Number of admission days per country}}$$

The following variables are included in the regression analyses. The clinical variables could vary over time and are included under the assumption that experiencing these events leads to an increased risk of transfusion and not vice versa.

- **Baseline variables:** sex, gestational age at birth, birth weight, multiple gestation, congenital anomalies, congenital bleeding disorders
- Clinical variables:** major bleeding, NEC, sepsis, mechanical ventilation, surgical procedure, postnatal age

5.2.2. Observed / expected prevalence rate ratio per country

The prevalence rate ratio per country is defined as the country's observed RBC transfusion day prevalence (as calculated in section 5.1) compared to the country's average expected RBC transfusion day prevalence rate.

$$\text{Prevalence rate ratio per country} = \frac{\text{Observed RBC day prevalence rate per country}}{\text{Average expected RBC day prevalence rate per country}}$$

Observed / expected prevalence rate ratios will be presented in an observed/expected funnel plot.

5.2.3 Case-mix adjusted prevalence rates

The standardized RBC transfusion day prevalence rates are defined as the prevalence rate ratio for a country multiplied with the overall unadjusted RBC prevalence rate.

$$\text{Case – mix adjusted prevalence rate per country} = \text{Prevalence rate ratio per country} * \text{overall unadjusted RBC prevalence rate}$$

We will present forest plots of the standardized RBC transfusion day prevalence rate, separately for the first 28 postnatal days of life and after the first 28 days of life, with corresponding non parametric bootstrap confidence intervals.

5.3 Cumulative incidence of receiving at least one RBC transfusion

The cumulative incidence (with 95% confidence interval) of receiving at least one RBC transfusion during the first 28 days of life will be calculated where death and discharge are considered as competing events. Infants that were already present at the NICU at the start of the study period are excluded, because the first RBC transfusion for these infants could have happened before the study period. Event time for infants who were transferred or discharged during the first 28 days of life were censored. The cumulative incidence was calculated in R with the package “cmprsk” using function “cuminc”.

6. ANALYSIS FOR OTHER STUDY OUTCOME MEASURES

6.1 Primary indications for RBC transfusion

We will present the primary indications for RBC transfusion per country using a 100% stacked bar chart. The indications reported under 'other indication' will be categorized where possible at the discretion of the primary investigators and will be reported.

6.2 Transfusion volume, duration and infusion rate

Transfusion infusion rates will be calculated by dividing the volume (mL/kg) by the transfusion duration (in hours). Transfusion infusion rates will be presented in two bubble plots, separately for the RBC transfusions given with primary indication "Threshold Haemoglobin/Hematocrit" and RBC transfusion given for any other primary indications.

6.3 Haemoglobin values prior to transfusion

We collected the last pre-transfusion Haemoglobin/Haematocrit value measured prior to RBC transfusion, if available within maximum 24 hours before transfusion. All Hb and Hct levels were converted to Hb in g/L using the following conversions: multiplying Hb in g/dL by 10, Hb in mmol/L by 16, Hct in percentage by 300, or Hct in L/L by 300. The available haemoglobin/haematocrit values for transfusions prior to transfusion will be presented in two box plots, separately for the RBC transfusions given with primary indication "Threshold Haemoglobin/Hematocrit" and RBC transfusion given for any other primary indications. The available pre-transfusion values will be stratified based on the respiratory support the infant received during transfusion, with the following categories: room air, low flow ($\leq 2L$) $FiO_2 > 0.21$, high flow ($> 2L$) $FiO_2 \leq 0.3$, high flow ($> 2L$) $FiO_2 > 0.3$, and invasive mechanical ventilation. Pre-transfusion values will not be plotted for postnatal age groups with 5 or less RBC transfusions administered per group.

We will present the proportion of pre-transfusion Hemoglobin values of RBC transfusions given with primary indication "Threshold Haemoglobin/Hematocrit" that are given above the liberal thresholds, at or between the liberal and restrictive thresholds, and below the restrictive thresholds tested in the ETTNO and TOP trials, respectively, for all the received respiratory support categories and postnatal age groups. The ETTNO thresholds are converted using the formula: $Hct (\%) * 300 = Hb (g/L)$, the TOP thresholds were converted using the formula: $Hb (g/dL) * 10 = Hb (g/L)$. If scenarios in this study could be categorized as both 'critical' or 'noncritical' according to the ETTNO trial or as both 'respiratory support' and 'no respiratory support' according to TOP trial, the highest liberal and lowest restrictive value are selected.

RBC transfusion thresholds (Hb in g/L) tested in the ETTNO and TOP trial (1, 2)

This study	ETTNO (Franz ea. JAMA 2020)		TOP (Kirpalani ea. NEJM 2020)	
Respiratory Support	Health state	RBC Thresholds	Respiratory Support	RBC Thresholds
Room air	Noncritical	<u>Day 1-7</u> Liberal: 105 Restrictive: 84 <u>Day 8-21</u> Liberal: 93 Restrictive: 72 <u>> Day 21</u> Liberal: 84 Restrictive: 63	No respiratory support	<u>Day 1-7</u> Liberal: 120 Restrictive: 100 <u>Day 8-14</u> Liberal: 110 Restrictive: 85 <u>> Day 15</u> Liberal: 100 Restrictive: 70
Low flow (≤ 2 L) FiO ₂ >0.21	Noncritical	<u>Day 1-7</u> Liberal: 105 Restrictive: 84 <u>Day 8-21</u> Liberal: 93 Restrictive: 72 <u>> Day 21</u> Liberal: 84 Restrictive: 63	No respiratory support or respiratory support **	<u>Day 1-7</u> Liberal: 130 Restrictive: 100 <u>Day 8-14</u> Liberal: 125 Restrictive: 85 <u>> Day 15</u> Liberal: 110 Restrictive: 70
High flow (>2L) FiO ₂ ≤ 0.3	Critical or noncritical*	<u>Day 1-7</u> Liberal: 123 Restrictive: 84 <u>Day 8-21</u> Liberal: 111 Restrictive: 72 <u>> Day 21</u> Liberal: 102 Restrictive: 63	Respiratory support	<u>Day 1-7</u> Liberal: 130 Restrictive: 110 <u>Day 8-14</u> Liberal: 125 Restrictive: 100 <u>> Day 15</u> Liberal: 110 Restrictive: 85
High flow (>2L) FiO ₂ >0.3 / CPAP / BiPAP / DuoPAP	Critical or noncritical*	<u>Day 1-7</u> Liberal: 123 Restrictive: 84 <u>Day 8-21</u> Liberal: 111 Restrictive: 72 <u>> Day 21</u> Liberal: 102 Restrictive: 63	Respiratory support	<u>Day 1-7</u> Liberal: 130 Restrictive: 110 <u>Day 8-14</u> Liberal: 125 Restrictive: 100 <u>> Day 15</u> Liberal: 110 Restrictive: 85
Invasive mechanical ventilation	Critical	<u>Day 1-7</u> Liberal: 123 Restrictive: 102 <u>Day 8-21</u> Liberal: 111 Restrictive: 90 <u>> Day 21</u> Liberal: 102 Restrictive: 81	Respiratory support	<u>Day 1-7</u> Liberal: 130 Restrictive: 110 <u>Day 8-14</u> Liberal: 125 Restrictive: 100 <u>> Day 15</u> Liberal: 110 Restrictive: 85

*Defined in ETTNO trial as critical if CPAP with FiO₂ >0.25 for >12 hours per 24 hours

**Defined in TOP trial as respiratory support if flow ≥ 1 liter per min.

6.4 RBC transfusion Haemoglobin increment

We also collected the post-transfusion Haemoglobin/Haematocrit value at the most recent measurement after the RBC transfusion, if available within maximum 24 hours after transfusion. All Haemoglobin or Hematocrit values are converted to Haemoglobin in g/L using the formulas as described in section 6.3. All RBC transfusions given with primary indication “Threshold Haemoglobin/Hematocrit” in which both pre-transfusion and post-transfusion Haemoglobin will be used for the following plots.

Transfusion increment will be calculated by subtracting post-transfusion Haemoglobin from pre-transfusion Haemoglobin. Transfusion increments will be plotted separately for the different transfusion volume categories as well as for all transfusions. Transfusion increment of a transfusion volume group will not be plotted if 5 or less RBC transfusions given at this volume.

6.5 Transfusion related adverse effects after RBC transfusion

In the absence of clear definitions of transfusion-associated side effects in preterm infants, local investigators were asked to register any perceived transfusion-associated adverse effects if they consider the adverse event to be potentially associated with the preceding transfusion.

We will report the percentage of RBC transfusions for which an adverse events was registered and the mean/median time between occurrence of the adverse effect and the RBC transfusion, in days. The observed adverse effects will be categorized where possible at the discretion of the primary investigators and will be reported in text.

7. GENERAL REMARKS

Reporting guidelines

The study results will be presented according to the recommendations of the STROBE guidelines.

Publication

The statistical analysis plan will be published in the ISRCTN registry.

8. STATEMENT


We hereby declare that this statistical analysis plan has been drafted prior to analysis of the INSPIRE data for the manuscript, and that this plan will be followed during the analysis phase. If any deviations from the plan are made, they will be incorporated and explained in an amendment.

Date:

Version:

Principal investigator:

Prof. dr. E. Lopriore



Biostatistician :

Prof. dr. Le Cessie



Coordinating investigator:

Nina Houben



9. REFERENCES

1. Franz AR, Engel C, Bassler D, Rüdiger M, Thome UH, Maier RF, et al. Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO Randomized Clinical Trial. JAMA. 2020;324(6):560-70.
2. Kirpalani H, Bell EF, Hintz SR, Tan S, Schmidt B, Chaudhary AS, et al. Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. New England Journal of Medicine. 2020;383(27):2639-51.
3. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046-67.